Navigation Links
Cell Therapeutics, Inc. Announces Institutional Investors Purchase Approximately $16.0 Million of Preferred Stock and Warrants
Date:4/27/2011

ghts on general corporate matters.

The closing of the offering is expected to occur on May 2, 2011, at which time the Company will receive the cash proceeds and deliver the securities.

Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq: RODM), acted as the exclusive placement agent for the offering.

A shelf registration statement relating to the shares of Series 12 Preferred Stock and warrants issued in the offering (and the shares of common stock issuable upon conversion of the Series 12 Preferred Stock and exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC").  A prospectus supplement under Rule 424 of the Securities Act of 1933, as amended, relating to the offering will be filed with the SEC.  Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting the Company at the following address: Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119.  This press release does not constitute an offer to sell or a solicitation of an offer to buy the Series 12 Preferred Stock or warrants (or the shares of common stock issuable upon conversion of the Series 12 Preferred Stock and exercise of the warrants).  No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading prices of the Company's securities. The risks and uncertainties include the risk that the purchase and sale of the Series 12 Preferred Stock and related warrants might not be consummated, investors might not exercise their
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Calif. , May 22, 2015 /PRNewswire/ ... the Company has commenced termination of its ... brodalumab with AstraZeneca (LON:AZN, STO:AZN and NYSE: ... inhibitor, is in development for patients with ... spondyloarthritis.  The decision was based on events ...
(Date:5/22/2015)... ORLANDO, Fla. , May 22, 2015 ... Copay Assistance Program. This program provides financial assistance for ... "We are pleased to announce the addition of the ... programs," stated Mark McGreevy , executive director. "With ... mission and vision of a world where no one ...
(Date:5/22/2015)... 2015  The U.S. Food and Drug Administration,s ... first biosimilar product approved in the ... in the contract manufacturing organization (CMO) industry, according ... geared to the production of small-molecular drugs and ... The healthcare market research publisher,s report, Biopharmaceutical ...
Breaking Medicine Technology:Amgen to terminate participation in co-development and commercialization of brodalumab 2Amgen to terminate participation in co-development and commercialization of brodalumab 3Amgen to terminate participation in co-development and commercialization of brodalumab 4Amgen to terminate participation in co-development and commercialization of brodalumab 5The Assistance Fund Adds Melanoma Assistance Program 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4
... Inc. (Nasdaq: MSON ), a developer of minimally ... used for the ablation of tumors and worldwide for ... first quarter ended September 30, 2009 financial results on ... President and Chief Executive Officer and Richard Zaremba, Senior ...
... Ind., Nov. 12 Zimmer Holdings, Inc. (NYSE: ZMH ... sell $1.0 billion of its senior unsecured notes in an ... due 2019 and $500.0 million of 5.75% notes due 2039. ... above their Treasury benchmark, and the 30-year notes were priced ...
Cached Medicine Technology:Misonix Schedules First Quarter 2010 Financial Results Conference Call; November 16, 2009 at 4:30 p.m. Eastern 2Zimmer Holdings, Inc. Agrees to Sell $1 Billion of Senior Notes 2
(Date:5/22/2015)... (PRWEB) May 22, 2015 Family, friends, ... Hospital’s world-renowned surgical oncologist, Dr. LaSalle D. Leffall, on ... The luncheon began after Grand Rounds in the hospital’s ... waited anxiously outside the auditorium, trying to keep the ... but if he sees me, he’ll know something is ...
(Date:5/22/2015)... R.I. (PRWEB) May 22, 2015 Memorial Day ... Amica Insurance is offering some tips to help ... Safety Council, there will be 383 traffic fatalities this Memorial ... from the National Highway Traffic Safety Association: , ... in the vehicle is wearing a seatbelt, whether they’re driving ...
(Date:5/22/2015)... 2015 Coco Libre, the Official Coconut Water ... Record at the 104th running of the race. On Sunday, ... served 315 people in one hour—one person about every 10 ... so true to the heart of the Bay Area, so ... luge to the finish line only made sense,” said Jennifer ...
(Date:5/22/2015)... West Hollywood, CA (PRWEB) May 22, 2015 ... at Sunset Plaza Dental announces that they ... in cosmetic, restorative and other dental treatments. At ... that interest them. Questions regarding what certain treatments ... can also be covered during this initial appointment. ...
(Date:5/22/2015)... sweetFrog Enterprises, LLC. is pleased to announce the ... now the 16th sweetFrog store located in the Lone Star ... on the Inc. 500 list of fastest growing companies in ... East Texas for 20 years and love the natural beauty ... and nearby Palestine, sweetFrog locations. “We are really excited about ...
Breaking Medicine News(10 mins):Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:Coco Libre Ice Luge Sets New World Record at Bay to Breakers 2Health News:West Hollywood Dental Office, Sunset Plaza Dental is Now Offering Complimentary Consultations 2Health News:sweetFrog Opens New Location in Jacksonville, Texas 2
... By Serena Gordon HealthDay Reporter , FRIDAY, ... helped prevent or slow the progression of type 1 diabetes ... too early to say if the results might apply to ... the immune system,s response to newly developing diabetes, and reduced ...
... HealthDay Reporter , FRIDAY, May 11 (HealthDay News) ... health, reducing stress levels and contributing to better focus, a ... Irvine, and the U.S. Army found that a group of ... five days experienced more natural, variable heart rates and switched ...
... a concentrated, highly targeted dose of radiation to the ... area, with no adverse effects on survival and a ... the ten-year results of a randomised trial, Professor Csaba ... Institute of Oncology, Budapest, will tell the World Congress ...
... KU Leuven, succeeded in undoing the effect of one ... vitamin K2. His discovery gives hope to Parkinson,s patients. ... Northern Illinois University (US) and will be published this ... Science ., "It appears from our research that administering ...
... Denise Mann HealthDay Reporter , THURSDAY, May 10 ... marrow stem cells to enhance their healing potential may help ... small study suggests. Researchers developed the treatment by ... process helped increase the amount of immune cells and stem ...
... Inducing labor after a woman has been pregnant for more ... before, during or shortly after birth without increasing the need ... born after induced labor were also more likely to require ... led by Sarah Stock of the School of Women and ...
Cached Medicine News:Health News:Oxygen Therapy Slows Type 1 Diabetes in Mice, Study Says 2Health News:Oxygen Therapy Slows Type 1 Diabetes in Mice, Study Says 3Health News:'Email Vacations' Boost Job Productivity, Lower Stress: Study 2Health News:'Email Vacations' Boost Job Productivity, Lower Stress: Study 3Health News:Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer 2Health News:Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer 3Health News:Vitamin K2: New hope for Parkinson's patients? 2Health News:Stem Cell Study Shows Promising Results Against Heart Failure 2Health News:Stem Cell Study Shows Promising Results Against Heart Failure 3Health News:Induced Labor Late in Pregnancy Has Pros, Cons 2
This is an economical (portable) microtome designed for fast and accurate sectioning. The specimen rise is automatic and accurate with each handle movement. Section thickness from 5 to 40 microns. ...
Disposable Feather Blades, 50 per pack...
Fine abrasive for knife sharpening, 6 grams net...
Knife sharpening back for Standard Knife, C Profile...
Medicine Products: